Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-955176 + ATV + DTG in Treatment-Experienced HIV-1
NCT02386098Phase 2Terminated
- Sponsor
- ViiV Healthcare
- Start
- Jul 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of BMS-955176 in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <40 Copies Per Milliliter at 24 weeks. Started Jul 2015; status: terminated.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02386098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386098.